The rising prevalence in GLP-1 agonists for diabetes has generated a discussion about delivery routes : transdermal systems versus capsules. Usually , GLP-1 drugs were exclusively available in pill form, but the introduction of transdermal delivery offers a different choice . Transdermal systems